bioXXmed AG (FRA:T5O0)
Germany
· Delayed Price · Currency is EUR 0.0220
-0.0180 (-45.00%)
At close: Dec 4, 2025
bioXXmed AG Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 0.02 | 0 | 0.02 | 0.01 | 0.04 | 0.04 | Upgrade
|
| Revenue Growth (YoY) | 310.44% | -79.93% | 42.27% | -72.59% | 23.96% | -0.50% | Upgrade
|
| Gross Profit | 0.02 | 0 | 0.02 | 0.01 | 0.04 | 0.04 | Upgrade
|
| Selling, General & Admin | 0.02 | 0.01 | 0.01 | 0 | 0.55 | 0.78 | Upgrade
|
| Other Operating Expenses | 0.68 | 0.86 | 0.82 | 0.83 | 1.01 | 1.08 | Upgrade
|
| Operating Expenses | 0.79 | 0.88 | 0.82 | 0.84 | 1.61 | 1.87 | Upgrade
|
| Operating Income | -0.77 | -0.87 | -0.81 | -0.82 | -1.57 | -1.84 | Upgrade
|
| Interest Expense | -0 | - | - | -0.04 | -0 | -0 | Upgrade
|
| Interest & Investment Income | - | - | 0.02 | 0.03 | 0 | 0 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.01 | 0 | - | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -0.76 | -0.87 | -0.79 | -0.83 | -1.57 | -1.84 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.13 | -0.13 | -20.16 | - | -2.49 | - | Upgrade
|
| Pretax Income | -0.89 | -1 | -20.95 | -0.83 | -4.06 | -1.84 | Upgrade
|
| Net Income | -0.89 | -1 | -20.95 | -0.83 | -4.06 | -1.84 | Upgrade
|
| Net Income to Common | -0.89 | -1 | -20.95 | -0.83 | -4.06 | -1.84 | Upgrade
|
| Shares Outstanding (Basic) | 1 | 1 | 1 | 1 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 1 | 1 | 1 | 1 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 164.59% | 164.59% | - | 27.54% | - | 15.39% | Upgrade
|
| EPS (Basic) | -0.66 | -0.73 | -40.78 | -1.62 | -10.08 | -4.57 | Upgrade
|
| EPS (Diluted) | -0.66 | -0.73 | -40.78 | -1.62 | -10.08 | -4.57 | Upgrade
|
| Free Cash Flow | - | -0.92 | -0.73 | -0.91 | - | -1.66 | Upgrade
|
| Free Cash Flow Per Share | - | -0.67 | -1.42 | -1.78 | - | -4.12 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -3750.23% | -24950.87% | -4633.08% | -6727.67% | -3516.49% | -5107.18% | Upgrade
|
| Profit Margin | -4347.37% | -28540.14% | -120369.63% | -6783.58% | -9095.43% | -5108.88% | Upgrade
|
| Free Cash Flow Margin | - | -26223.88% | -4194.44% | -7473.42% | - | -4613.89% | Upgrade
|
| EBITDA | -0.64 | -0.79 | -0.8 | -0.82 | -1.55 | -1.82 | Upgrade
|
| D&A For EBITDA | 0.13 | 0.09 | 0.01 | 0.01 | 0.02 | 0.02 | Upgrade
|
| EBIT | -0.77 | -0.87 | -0.81 | -0.82 | -1.57 | -1.84 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.